Form 4: Agenus CEO Garo Armen Opts for Stock Salary

Agenus Inc.'s Chairman and CEO, Garo H. Armen, received 4,216 shares of common stock as salary, demonstrating alignment with shareholder interests.

Summary

• Garo H. Armen, Chairman and Chief Executive Officer of Agenus Inc., acquired 4,216 shares of Agenus common stock.
• The transaction occurred on October 17, 2025, with shares valued at $3.88 each, which was the closing price on that date.
• This acquisition represents Dr. Armen's salary for the pay period ending October 17, 2025, paid in stock instead of cash, a request approved by the Agenus Inc. Compensation Committee.
• The shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance.
• Following this transaction, Dr. Armen directly beneficially owns 286,609 shares of common stock.
• Indirect beneficial ownership includes 31,298 shares held in Dr. Armen's IRA accounts and 28,950 shares held through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where Dr. Armen is a trustee or general partner.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of management and shareholder interests through stock-based compensation, suggesting confidence in the company's future. It's a routine transaction but carries a positive signal.

Positives

• Management's decision to receive salary in stock aligns their financial interests directly with those of shareholders, indicating confidence in the company's future performance.
• The shares acquired are fully vested on the date of issuance, providing immediate and unrestricted ownership to the CEO.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider compensation transaction.

Management Comments

• "At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash."

Industry Context

This filing reflects a common practice in the biotechnology and pharmaceutical industries where executive compensation often includes equity components. This strategy aims to align management's long-term incentives with the company's performance and shareholder value, a standard approach across various sectors to foster commitment and drive growth.

Comparison to Industry Standards

• The practice of compensating executives with company stock is a widely adopted standard across industries, including biotechnology, to align management's interests with those of shareholders.
• Companies like Regeneron Pharmaceuticals (REGN) and Amgen (AMGN) frequently utilize equity-based compensation, such as restricted stock units or stock options, for their leadership teams to incentivize long-term performance and retention.
• While the specific details of Dr. Armen's stock-for-salary arrangement are unique to Agenus, the underlying principle of using equity as a compensation tool is consistent with global benchmarks for executive remuneration in publicly traded companies.

Corporate Governance

Related Party Transactions

• Garo H. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT, which holds 23,950 shares of Agenus common stock.
• Dr. Armen is a general partner in Pixie Partners, a General Partnership, which owns 5,000 shares of Agenus common stock. Dr. Armen disclaims beneficial ownership to the extent of his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The CEO's decision to take salary in stock signals confidence in the company's future, potentially fostering positive sentiment and aligning management's interests with shareholder returns.
• Management: The compensation structure reinforces the CEO's commitment to the company's long-term performance and equity value.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where the CEO received salary in stock. While it signals management's confidence and aligns interests with shareholders, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It's a positive but not transformative event.

Keywords

Agenus Inc., AGEN, Garo H. Armen, Insider Trading, Form 4, Stock Compensation, CEO, Director, Equity Incentive Plan